Biorestorative Therapies Stock Forum

$Biorestorative Therapies (BRTX.US)$
BRTX-100 Front and Center at ORS 2025
BioRestorative Therapies (NASDAQ:BRTX) presented new blinded preliminary data from its Phase 2 clinical trial of BRTX-100 at the Orthopaedic Research Society annual meeting. The data, now covering 15 patients with chronic lumbar disc disease (cLDD), showed significant improvements:
- Pain reduction (VAS): 71.20% at 26 weeks and 73.58% at 52 weeks
- Function improvement (ODI): 69.04% at 26 weeks and 65.16% at 52 weeks
-...

$Biorestorative Therapies (BRTX.US)$ BRTX-100 Front and Center at ORS 2025
GlobeNewswire· 9 mins ago
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health" presentation –
– Among other positive preliminary data analyses, comparison of MRI images to baseline potentially demonstrate disc microenvironment remodeling –
MELVILLE, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorativ...

$Biorestorative Therapies (BRTX.US)$ Reuters
Just
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting Thermostem® Metabolic Disease Program

$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Thursday, 5th December at 6:45 am
– Covers cGMP manufacturing processes –
– Expected to provide protection until April 29, 2040 –
MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem...

$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints –
– Patient reported efficacy outcomes show a material decrease in pain and increase in function –
– If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points -
...

$Biorestorative Therapies (BRTX.US)$
MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has received a provisional license from the New York State Department of Health (“NYSDOH”) for the pro...

$Biorestorative Therapies (BRTX.US)$ Reuters· just
BioRestorative Therapies Receives Expanded Tissue License From New York State Department of Health

$Biorestorative Therapies (BRTX.US)$
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
BioRestorative Therapies has received a Notice of Allowance from the Israel Patent Office for its ThermoStem® technology platform. This marks the 14th international patent outside the U.S. for this technology. The patent covers brown adipose derived stem cell (BADSC) aggregates, encapsulation systems, and treatment methods. The company believes ThermoStem®-based BA...